Skip to content

Travere Therapeutics, Inc. TVTX Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

PVL
Palvella TherapeuticsPVLA
-$15.76M-92.3%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$63.74M+12.5%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$159.56M-254%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$105.91M-22.2%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$34.07M+47.1%
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.2B+72.3%

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Travere Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Travere Therapeutics, Inc. (TVTX) reported comprehensive income (loss), net of tax, attributable to parent of -$36.98M in Q1 2026.
How has Travere Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Travere Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent increased by 11.9% year-over-year, from -$41.99M to -$36.98M.
What is the long-term trend for Travere Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a -36.5% compound annual growth rate (CAGR), from -$179.75M to -$29.25M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric captures changes in equity resulting from non-owner sources that are not included in traditional net income, such as unrealized gains or losses on financial instruments or foreign currency translation adjustments. It provides a more holistic view of the company's financial health by accounting for volatility in assets and liabilities that do not flow through the standard income statement. Tracking this figure helps investors understand the broader impact of market fluctuations on the company's total equity position.